Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum IMV Inc IMVIQ

IMV Inc. is a Canada-based company. The Company has no business operations.

GREY:IMVIQ - Post Discussion

IMV Inc > mRNA vs DPX
View:
Post by antigua1987 on Jul 27, 2021 9:56am

mRNA vs DPX

Afraid to ask: are these 2 'delivery' platforms competing in the same space, ie priming immune systems for bulked up responses, whether preventative or curative, to viral infections, cancer, etc?

And If yes, and seeing obvious success of mRNA tech, where does this leave IMV's tech? Is it differentiated enough?

PS - be kind, Imv's going through another existential crisis atm.
Comment by jakayo4 on Jul 27, 2021 12:31pm
This post has been removed in accordance with Community Policy
Comment by Jthom376 on Jul 27, 2021 1:52pm
How many have died with mRNA? Oh ya that's a question no one would ask. But beyond that. Duration of action and immunity is supposedly significant with the DPX platform. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities